AbbVie Secures European Approval for Epcoritamab with R2 in Follicular Lymphoma

AbbVie Gains Approval for Innovative Cancer Therapy in Europe

AbbVie has recently celebrated a significant achievement as it announced the European Commission's approval for the combination therapy of Epcoritamab with Lenalidomide and Rituximab (known as R2) to treat adult patients suffering from relapsed or refractory follicular lymphoma (R/R FL). This groundbreaking treatment represents the first dual-specific antibody combination therapy approved in Europe for these patients, showcasing an alternative to traditional chemotherapy options.

The approval follows promising results from the pivotal Phase 3 EPCORE FL-1 trial, where fixed-duration treatment with Epcoritamab + R2 demonstrated statistically significant improvements in both progression-free survival and overall response rates in comparison with the standard R2 regimen. Notably, around three-quarters of the patients under this combination therapy experienced complete remission.

According to Dr. Catherine Thieblemont, head of the Hemato-Oncology Department at Paris Cité University, this approval comes at a critical moment as patients diagnosed with follicular lymphoma are often in dire need of more treatment options due to the cancer's tendency to relapse and the progressively shorter durations of remission. The data from the EPCORE FL-1 trial suggests that Epcoritamab + R2 may provide sustained efficacy without the typical side effects associated with chemotherapy, fundamentally changing the treatment landscape for these patients.

Key Findings from the EPCORE FL-1 Trial

The EPCORE FL-1 trial was a significant, open-label Phase 3 non-blinded study that examined the safety and efficacy of Epcoritamab + R2 against R2 alone in adults with R/R FL. The results indicated a remarkable 79% reduction in the risk of disease progression or death for the combination therapy compared to the R2 group (hazard ratio of 0.21). Furthermore, the overall response rate (ORR) was notably higher in the Epcoritamab + R2 cohort at 96%, compared to 81% in the R2 cohort.

The study also found that the rate of complete response (CR) was significantly higher in the combination therapy group, with 74% of patients achieving CR compared to just 43% in the R2 group. Additionally, the safety profile of Epcoritamab + R2 aligned with the known safety profiles of both therapies, with common side effects including neutropenia, rash, and fatigue. Serious adverse events were reported in 44% of the patients receiving the combination therapy, yet the overall outcomes suggest an effective treatment paradigm for managing this challenging cancer.

Dr. Roopal Thakkar, Executive Vice President and Chief Scientific Officer at AbbVie, emphasized the need for novel treatment options for patients suffering from R/R follicular lymphoma. The recent approval signifies an important stride toward offering effective treatment alternatives for European patients, potentially boosting outcomes in this particularly challenging patient demographic.

Understanding Follicular Lymphoma

Follicular lymphoma (FL) is a type of indolent non-Hodgkin lymphoma characterized by the proliferation of B lymphocytes. Representing the second most common form of NHL, FL accounts for 20-30% of all NHL cases, with European populations experiencing a substantially higher incidence rate of 11-29% compared to 2-18% in n- European groups. Despite being classified as indolent, FL is notoriously difficult to treat, and standard treatment options are limited beyond third-line therapies.

The cycle of relapse and treatment can be relentless for patients diagnosed with FL, prompting the need for innovative therapies like the newly approved Epcoritamab + R2. Dr. Mitchell Smith, Chief Medical Officer of the Follicular Lymphoma Foundation, highlighted the approval as a promising advancement that provides new hope to the FL community.

Moving Forward

As AbbVie continues to explore the potential of Epcoritamab across multiple treatment lines, they remain committed to improving treatment outcomes for patients battling this resilient form of lymphoma. With an expanding oncology portfolio, AbbVie is dedicated to harnessing innovative therapies aimed at combating both blood cancers and solid tumors, reflecting its broader mission to meet the pressing healthcare challenges of today.

For further details on AbbVie’s ongoing oncology efforts, visit AbbVie.